Stefano Verardi
YOU?
Author Swipe
View article: Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study
Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study Open
Purpose We assessed the effectiveness and safety of cefiderocol in patients with Gram-negative bacterial infections, excluding Acinetobacter spp., in the early access programme (EAP) in Spain. Methods The retrospective, multicentre PERSEUS…
View article: Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study
Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study Open
View article: P-1475. Real-World Effectiveness and Safety of Cefiderocol in the Treatment of Patients with Serious Gram-negative Bacterial Infections: Results of the PROVE Chart Review Study
P-1475. Real-World Effectiveness and Safety of Cefiderocol in the Treatment of Patients with Serious Gram-negative Bacterial Infections: Results of the PROVE Chart Review Study Open
Background The ongoing PROVE retrospective chart review study aims to assess real-world outcomes of cefiderocol treatment in patients with serious Gram-negative bacterial infections. Methods This is an interim analysis of hospitalized pati…
View article: 2752. Outcomes of Patients with <i>Stenotrophomonas maltophilia</i> infections treated with Cefiderocol in PROVE (Retrospective Cefiderocol Chart Review) Study
2752. Outcomes of Patients with <i>Stenotrophomonas maltophilia</i> infections treated with Cefiderocol in PROVE (Retrospective Cefiderocol Chart Review) Study Open
Background Gram-negative (GN) bacterial resistance remains an urgent global health problem. Cefiderocol (CFDC) has activity against Stenotrophomonas maltophilia (SM) isolates. PROVE is an ongoing international, retrospective study of CFDC …
View article: 2750. <i>Pseudomonas aeruginosa</i> infections treated with cefiderocol: associations of site of infection and time to first dose with outcomes in PROVE (Retrospective Cefiderocol Chart Review) Study
2750. <i>Pseudomonas aeruginosa</i> infections treated with cefiderocol: associations of site of infection and time to first dose with outcomes in PROVE (Retrospective Cefiderocol Chart Review) Study Open
Background Gram-negative (GN) bacterial resistance is a major global health problem. Cefiderocol (CFDC) is active against Pseudomonas aeruginosa (PA). PROVE is an international, retrospective study of CFDC use in Gram-negative infections (…
View article: Carbapenem-Resistant <i>Acinetobacter</i> spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic
Carbapenem-Resistant <i>Acinetobacter</i> spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic Open
Background Carbapenem-resistant Acinetobacter baumannii infections are difficult to treat and are a significant public health threat due to intrinsic/acquired resistance and limited treatment options. Methods A retrospective, observational…
View article: Assessment of the Haemostatic Potential of Platelets Readied for Transfusion
Assessment of the Haemostatic Potential of Platelets Readied for Transfusion Open